SCHEMBL2243204

SCHEMBL2243204

CCOC(=O)N(c1ccc(N)cc1)C(C)P(=O)(Oc1ccccc1)Oc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.43
PLAU P00749 2/20 0.43
PLAT P00750 2/20 0.43
PLG P00747 1/20 0.39
ELANE P08246 1/20 0.39
BTN3A1 O00481 4/20 0.39
CTDSP1 Q9GZU7 1/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ANPEP P15144 1/20 0.37
LAP3 P28838 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAOA P21397 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2249449 0.89 PLAU (0.53) F2PLAUPLATPLGELANE
SCHEMBL2245473 0.87 PLAU (0.42) F2PLAUPLATPLGELANE
SCHEMBL13736066 0.82 PLAU (0.37) F2PLAUPLATPLGELANE
Trifluoroacetic Acid SCHEMBL13736752 0.80 PLAU (0.37) F2PLAUPLATPLGELANE
Trifluoroacetic Acid SCHEMBL13736056 0.77 PLAU (0.35) F2PLAUPLATPLGELANE
Trifluoroacetic Acid SCHEMBL13736165 0.75 PLAU (0.32) F2PLAUPLAT
Trifluoroacetic Acid SCHEMBL13738338 0.75 PLAU (0.32) F2PLAUPLAT
SCHEMBL24225368 0.71 ELANE (0.49) F2PLAUPLATPLGELANE
SCHEMBL11109783 0.71 CTDSP1 (0.49) CTDSP1LMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL28138500 0.71 ALDH1A1 (0.60) CTDSP1LMNASMN1; SMN2CYP1A2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940856-B1 NOVEL UROKINASE INHIBITORS UNIV ANTWERPEN (BE) 2014-10-08 EP disclosed
US-8003627-B2 Urokinase inhibitors UNIVERSITEIT ANTWERPEN (BE) 2011-08-23 US disclosed
US-20080312191-A1 Novel Urokinase Inhibitors UNIVERSITEIT ANTWERPEN (BE) 2008-12-18 US disclosed
EP-1940856-A1 NOVEL UROKINASE INHIBITORS Universiteit Antwerpen (BE) 2008-07-09 EP disclosed
WO-2007045496-A1 NOVEL UROKINASE INHIBITORS UNIVERSITEIT ANTWERPEN (BE) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312191-A1 Novel Urokinase Inhibitors PLAU, PLAUR, SERPINE1 F2 241/4885PLAU 1/4885PLAT 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.